Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +34 vs. previous quarter
- 109
- 13F valueReported value at the end of Q2 2026
- $579.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IMMX, Q2 2026
No superinvestor reported holding IMMX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immix Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 (view filing) | Dec 10 | Same day | Rachman Ilya MCEO and Chairman | PPurchase | +746 | $6.67 | +$4.98K | +0.1%1.14M after | |
| Dec 10, 2025 (view filing) | Dec 10 | Same day | Morris Gabriel SCFO | PPurchase | +770 | $6.58 | +$5.07K | +0.3%291.4K after | |
| Sep 17, 2025 (view filing) | Sep 17 | Same day | Rachman Ilya MCEO and Chairman | PPurchase | +2.50K | $2.02 | +$5.05K | +0.2%1.14M after | |
| Sep 17, 2025 (view filing) | Sep 16 | 1 day | Morris Gabriel SCFO | PPurchase | +2.60K | $1.97 | +$5.12K | +0.9%290.7K after | |
| Jun 20, 2025 (view filing) | Jun 18 | 2 days | Rachman Ilya MCEO and Chairman | PPurchase | +2.18K | $2.30 | +$5.01K | +0.2%1.14M after | |
| Jun 20, 2025 (view filing) | Jun 18 | 2 days | Morris Gabriel SCFO | PPurchase | +2.23K | $2.28 | +$5.07K | +0.8%288.1K after | |
| Dec 26, 2024 (view filing) | Dec 20-23 | 6 days | Hsu JasonDirector | PPurchase | +47.7K | $2.19 | +$104.3K | +5.6%893.0K after | 2 lots |
| Aug 26, 2024 (view filing) | Aug 21-22 | 5 daysLate | Hsu JasonDirector | PPurchase | +23.1K | $2.24 | +$51.7K | +2.8%845.3K after | 2 lots |
| Aug 19, 2024 (view filing) | Aug 16 | 3 days | Ng CareyDirector | PPurchase | +10.0K | $1.86 | +$18.6K | +100.0%20.0K after | |
| Jul 31, 2024 (view filing) | Jul 18-24 | 13 daysLate | Hsu JasonDirector | PPurchase | +9.20K | $2.12 | +$19.5K | +1.1%822.2K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Immix Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 9,783,192 | $100.8M | 0.04% | +9,783,192 | New |
| Saturn V Capital Management LLC | 4,658,429 | $48.0M | 6.89% | +964,844+26.1% | Added |
| Eventide Asset Management, LLC | 3,891,019 | $40.1M | 0.54% | +1,342,000+52.6% | Added |
| State Street Corp | 2,996,935 | $30.9M | 0.00% | +2,805,025+1,461.6% | Added |
| BlackRock, Inc. | 2,989,972 | $30.8M | 0.00% | +2,521,595+538.4% | Added |
| Deep Track Capital, LP | 2,775,000 | $28.6M | 0.42% | +2,775,000 | New |
| Vanguard Capital Management LLC | 2,507,122 | $25.8M | 0.00% | +719,128+40.2% | Added |
| Opaleye Management Inc. | 2,345,000 | $24.2M | 2.19% | +2,345,000 | New |
| Millennium Management LLC | 2,066,426 | $21.3M | 0.01% | +316,226+18.1% | Added |
| UBS Group AG | 1,941,817 | $20.0M | 0.00% | +1,864,985+2,427.4% | Added |